RxDoctor Payments Data

Nelson Kalaf, MD

Internal Medicine · Mission, TXNPI 1205858107

Payments from drug & device makers

$1,280in general payments, 2019–2025

Across 23 payments — averaging $55.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$466
  • Lilly USA, LLC$249
  • Novo Nordisk$228
  • Medtronic$101
  • Pfizer$59
  • Amgen$45
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$1,25398%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,280 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$61,202
Medicare patients
156
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide214$233,120
MounjaroTirzepatide191$212,373
JardianceEmpagliflozin85$107,392
TradjentaLinagliptin88$85,856
GlyxambiEmpagliflozin/Linagliptin79$84,141
JanuviaSitagliptin Phosphate80$80,168
XareltoRivaroxaban69$77,821
EliquisApixaban87$77,616
FarxigaDapagliflozin Propanediol58$63,259
TrulicityDulaglutide47$57,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$37,296
Synjardy XrEmpagliflozin/Metformin Hcl24$35,317
LinzessLinaclotide38$30,900
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog46$30,811
ProliaDenosumab18$30,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$249$269,504238 claims
Novo NordiskOzempic$228$233,120214 claims
Johnson & JohnsonXarelto$466$77,82169 claims
PfizerEliquis$59$77,61687 claims
AbbVieLinzess$13$30,90038 claims
AmgenProlia$45$30,14318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →